Lin Shen
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Gastric Cancer Management and Outcomes
Papers in
- Oncology 167
- Cancer Immunotherapy and Biomarkers 59
- Colorectal Cancer Treatments and Studies 51
- HER2/EGFR in Cancer Research 16
-
- Gastric Cancer Management and Outcomes 90
- Co-authors
- Yoon‐Koo Kang (8 shared papers)Atsushi Ohtsu (7 shared papers)Yung‐Jue Bang (6 shared papers)Hyun Cheol Chung (3 shared papers)Eric Van Cutsem (11 shared papers)Akira Sawaki (2 shared papers)Taroh Satoh (2 shared papers)Andrea Feyereislova (1 shared paper)
- Journals
- Annals of Oncology (44 papers)Journal of Clinical Oncology (16 papers)European Journal of Cancer (10 papers)Medical Oncology (9 papers)BMC Cancer (9 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Lin Shen
375 papers receiving 20.6k citations
Lin Shen's Hit Papers
Peers
Comparison fields: 5 of 143
- Oncology 6.3k
- Pulmonary and Respiratory Medicine 7k
- Cancer Research 1.4k
- Gastroenterology 698
- Surgery 3k
Countries citing papers authored by Lin Shen
This map shows the geographic impact of Lin Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Shen more than expected).
Fields of papers citing papers by Lin Shen
This network shows the impact of papers produced by Lin Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Shen. The network helps show where Lin Shen may publish in the future.
Co-authors
The 25 scholars most cited alongside Lin Shen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 398 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Hit paper breakdown → | 2010 | 5931 |
| 2 | Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells Hit paper breakdown → | 2020 | 1057 |
| 3 | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Hit paper breakdown → | 2020 | 837 |
| 4 | The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021 Hit paper breakdown → | 2021 | 488 |
| 5 | Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study Hit paper breakdown → | 2013 | 406 |
| 6 | Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study Hit paper breakdown → | 2018 | 397 |
| 7 | Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality Hit paper breakdown → | 2012 | 391 |
| 8 | 2011 | 342 | |
| 9 | 2013 | 338 | |
| 10 | 2018 | 327 | |
| 11 | Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial Hit paper breakdown → | 2021 | 313 |
| 12 | 2020 | 299 | |
| 13 | Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) Hit paper breakdown → | 2021 | 256 |
| 14 | Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study Hit paper breakdown → | 2022 | 226 |
| 15 | The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023 Hit paper breakdown → | 2023 | 224 |
| 16 | Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial Hit paper breakdown → | 2019 | 207 |
| 17 | 2010 | 169 | |
| 18 | 2020 | 167 | |
| 19 | 2021 | 165 | |
| 20 | 2016 | 161 |
About Lin Shen
Lin Shen is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Gastroenterology, Surgery and Epidemiology, having authored 398 papers that have together received 21k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (90 papers), Cancer Immunotherapy and Biomarkers (59 papers), Colorectal Cancer Treatments and Studies (51 papers), Esophageal Cancer Research and Treatment (32 papers), Gastrointestinal Tumor Research and Treatment (26 papers), Neuroendocrine Tumor Research Advances (26 papers), HER2/EGFR in Cancer Research (16 papers) and Helicobacter pylori-related gastroenterology studies (9 papers). The work is most often cited by research in Oncology (6.3k citations), Pulmonary and Respiratory Medicine (7k citations), Cancer Research (1.4k citations), Gastroenterology (698 citations) and Surgery (3k citations). Lin Shen has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Yoon‐Koo Kang, Atsushi Ohtsu, Yung‐Jue Bang, Hyun Cheol Chung, Eric Van Cutsem, Akira Sawaki, Taroh Satoh, Andrea Feyereislova, Michaela Lehle and Florian Lordick. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, Medical Oncology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.